Vir Biotechnology Director Departs Board

Ticker: VIR · Form: 8-K · Filed: 2024-09-10T00:00:00.000Z

Sentiment: neutral

Topics: director-departure, board-changes, corporate-governance

Related Tickers: REGN

TL;DR

Vir Bio director Yancopoulos out, board shakeup underway.

AI Summary

Vir Biotechnology, Inc. announced on September 6, 2024, the departure of Dr. George Yancopoulos from its Board of Directors. Dr. Yancopoulos, who also served as Chief Scientific Officer and President of Regeneron Pharmaceuticals, Inc., resigned from his position. The company also reported on the completion of an acquisition or disposition of assets and provided updates on compensatory arrangements for certain officers.

Why It Matters

The departure of a key director like Dr. Yancopoulos, especially one with significant ties to another major biotech firm, could signal strategic shifts or potential conflicts of interest.

Risk Assessment

Risk Level: medium — The departure of a high-profile director and potential strategic implications warrant a medium risk assessment.

Key Players & Entities

FAQ

Why did Dr. George Yancopoulos resign from the Board of Directors of Vir Biotechnology, Inc.?

The filing does not explicitly state the reason for Dr. Yancopoulos's resignation, only that he departed from his position on the Board of Directors as of September 6, 2024.

What other roles does Dr. George Yancopoulos hold?

Dr. George Yancopoulos also serves as Chief Scientific Officer and President of Regeneron Pharmaceuticals, Inc.

What other items are reported in this 8-K filing?

This 8-K filing also reports on the completion of an acquisition or disposition of assets, departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, Regulation FD Disclosure, and Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on September 6, 2024.

What is Vir Biotechnology, Inc.'s state of incorporation and fiscal year end?

Vir Biotechnology, Inc. is incorporated in Delaware and its fiscal year ends on December 31.

From the Filing

0001628280-24-039948.txt : 20240910 0001628280-24-039948.hdr.sgml : 20240910 20240910081048 ACCESSION NUMBER: 0001628280-24-039948 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20240906 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240910 DATE AS OF CHANGE: 20240910 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 241288777 BUSINESS ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 8-K 1 vir-20240906.htm 8-K vir-20240906 FALSE 0001706431 0001706431 2024-09-06 2024-09-06 0001706431 exch:XNAS 2024-09-06 2024-09-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________ FORM 8-K ________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2024 ________________________________________ Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) ________________________________________ Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1800 Owens Street , Suite 900 San Francisco , California 94158 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: ( 415 ) 906-4324 (Former Name or Former Address, if Changed Since Last Report) ________________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.0001 par value VIR Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 2.01. Completion of Acquisition or Disposition of Assets. On September 9, 2024, Vir Biotechnology, Inc. (the “Company” or “Vir”) and Amunix Pharmaceuticals, Inc., a Sanofi company (“Sanofi”) closed the transaction contemplated by the previously-announced License Agreement entered into between the parties on July 31, 2024 (the “Transaction” and the “Agre

View on Read The Filing